\nDescription \nAtorvastatin calcium is a synthetic lipid-lowering agent. Atorvastatin is an \ninhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. \nThis enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and \nrate-limiting step in cholesterol biosynthesis. \n \nIndications \nAtorvastatin is indicated \n1. As an adjunct to diet to reduce elevated total cholesterol, LDL-C, \napolipoprotein B, and triglycerides (TG) levels and to increase HDL-C in \npatients with primary hypercholesterolemia and mixed dyslipidemia. \n2. As an adjunct to diet for the treatment of patients with elevated serum TG levels. \n3. For the treatment of patients with primary dysbetalipoproteinemia who do \nnot respond adequately to diet. \n4. To reduce total cholesterol and LDL-C in patients with homozygous familial \nhypercholesterolemia as an adjunct to other lipid-lowering treatments. \n5. As an adjunct to diet to reduce total-C, LDL-C, and apolipoprotein B levels in \nboys and postmenarchal girls, 10 to 17 years of age, with heterozygous \nfamilial hypercholesterolemia. \n \nSupply \nXelpid??10 mg Tablet: Each box contains 3x10?s tablet \nXelpid??20 mg Tablet: Each box contains 1x10?s tablet \nXelpid??40 mg Tablet: Each box contains 1x10?s tablet